Foundational guide
FOXO4-DRI Side Effects: An Empty Dataset, Not a Clean One
No adverse events have been collected because no trial has collected them. What the mechanism predicts, what senolysis has already done in one disease model, and why contamination risk belongs to the batch.
FOXO4-DRI side effects are unknown in humans, and the distinction between unknown and absent is the whole content of this guide. An empty adverse-event dataset is not the same as a clean one.
What can be assessed is what the mechanism predicts, what senolysis has already been shown to do in at least one disease model, and a separate class of risk that belongs to the preparation rather than the molecule.
Supplier publishing lot-level data
FOXO4-DRI, Ascension Peptides
Two independent laboratories have certified this product, though on different batches. The code below halves the listed price on the vial.
The two published certificates cover different lots and disagree on fill: Kovera Labs assays batch 55-05260628 at 11.41 mg, MZ Biolabs assays lot 55-01260229 at 8.30 mg, both against a 10 mg label, moving the real figure between $5.87/mg and $8.07/mg. Endotoxin and sterility screens appear on the Kovera lot only, so testing scope here is a batch property rather than a product feature. The vendor spells the product FOX04 with a zero, including in the link.
- Kovera Labs and MZ Biolabs certificates, different lots
- Carriage free above $250
- Same-day dispatch before 2pm CST
Laboratory research material only, not for human consumption. FOXO4-DRI holds no marketing authorisation in any market and has never been administered in a registered human trial. Affiliate links: we may earn a commission at no additional cost to you. Figures checked September 2, 2026.
Why the dataset is empty
A side-effect profile is produced by a specific sequence: dose-ranging under monitoring, systematic adverse-event collection, laboratory surveillance, and eventually post-marketing reporting across a large exposed population.
Each stage generates information that could not have been derived from the mechanism, which is precisely why the sequence exists rather than being replaced by inference. Effects that appear only at scale, only in particular subpopulations, or only after prolonged exposure are invisible to reasoning.
FOXO4-DRI has completed none of these stages. It holds no marketing authorisation from the FDA, the EMA or the MHRA and has never been administered to a person in a registered study.
Anecdotal reports do not substitute. Material of unverified composition, used in uncontrolled conditions, frequently alongside other compounds and lifestyle change, cannot support causal attribution regardless of the sincerity of the reporter.
What the mechanism predicts
The peptide disrupts the FOXO4 and p53 interaction, releasing p53 to trigger apoptosis in senescent cells. The predictable concerns all follow from asking what that removal costs.
Senescence is a tumour-suppressive mechanism. A cell that has accumulated potentially oncogenic damage is withdrawn permanently from the replicative pool. Eliminating senescent cells eliminates a population that is being restrained for a reason.
Senescent cells also participate in wound healing and tissue remodelling, appearing transiently at injury sites before natural clearance. Interference with that process has no obvious benefit.
Selectivity is comparative rather than absolute. The peptide acts preferentially on senescent cells, and the margin has not been characterised in a human body. p53 is central to numerous normal cellular processes, so a compound modulating its localisation is not acting on an isolated target.
The finding that runs the other way
The most informative safety data available concerns senolysis as a strategy rather than this peptide specifically.
A 2023 report in Circulation examined senescent-cell clearance in pulmonary hypertension and found that eliminating senescent cells could promote the development and progression of the disease. That is an experimental demonstration that the intervention is context-dependent and can worsen a condition rather than improve it.
This carries more weight than a theoretical objection because it is a result rather than a prediction. Whether the same dynamic operates in other tissues, or in a person with undiagnosed vascular disease, has not been investigated.
The 2017 study described its in-vivo dosing as being at a level where the peptide was well tolerated in the animals. That is a statement about mice in a short laboratory experiment and does not transfer to humans.
Contamination risk is a batch property
A separate risk class has nothing to do with mechanism and everything to do with manufacturing.
Research-grade material is not produced under the controls governing injectable medicines. The relevant hazards are bacterial endotoxin, which survives autoclaving and provokes a strong inflammatory response, and microbial contamination. Both belong to a specific production lot.
This is where a certificate functions as a safety document rather than a purchasing one, and where the two published reports for this product differ materially.
| Screen | Kovera 55-05260628 | MZ Biolabs 55-01260229 |
|---|---|---|
| Purity | 99.411% | 99.97% |
| Net content | 11.41 mg | 8.30 mg |
| Identity confirmation | LC-MS | MS within HPLC-UV-MS |
| Endotoxin | Pass, at or below 0.5 EU/mL | Not performed |
| Microbial sterility | No growth | Not performed |
Frequently asked questions
- What are the side effects of FOXO4-DRI?
- Unknown in humans. No registered trial has collected adverse events, so no safety profile exists. That is an empty dataset rather than a clean one.
- Is clearing senescent cells inherently safe?
- No. Senescence suppresses tumour formation and contributes to wound healing. A 2023 Circulation study found senescent-cell elimination promoted pulmonary hypertension development and progression.
- Is this product endotoxin tested?
- One published batch is and one is not. The Kovera report on batch 55-05260628 includes endotoxin and sterility screens; the MZ Biolabs report on lot 55-01260229 covers purity and quantity only.
- Do the animal studies establish tolerability?
- No. The 2017 paper described dosing as well tolerated in mice at the levels used, over a short experiment. That is a limited observation in another species.
Limitations of the evidence
No human safety data exists for FOXO4-DRI. The mechanistic concerns described here are predictions rather than observations, and the animal tolerability statements come from short experiments under laboratory conditions. Absence of reported harm in this literature reflects absence of human study, not evidence of safety.
References
Citations are annotated with an evidence tier reflecting study design and replication. See Methodology for criteria.
- 1.Baar MP, Brandt RMC, Putavet DA, et al. · Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging · Cell · 2017PMID 28340339Preclinical
- 2.Circulation · Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression · Circulation · 2023PMID 36515093Preclinical
- 3.Frontiers in Bioengineering and Biotechnology · Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes · Frontiers in Bioengineering and Biotechnology · 2021PMID 33996787Preclinical